Clinical trial
Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer
NCT00078494 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00078494 |
|---|---|
| Title | Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer |
| Official title | Phase I/II Trial of Latent Membrane Protein (LMP) - 2 Immunization for the Assessment of the Natural History and the Immunization-Induced Immunological Response in Patients at High Risk for Recurrence of Anaplastic Nasopharyngeal Cancer |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Nasopharyngeal Neoplasms |
| Intervention type | Drug |
| Interventions | EBV-LMP-2 |
| Enrollment | 99 |
| Start date | Feb 1, 2004 |
| Completion | May 1, 2006 |
| First posted | Mar 1, 2004 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: